Literature DB >> 3319587

The spectrum and significance of autoantibodies reacting with the thyrotropin receptor.

M Zakarija1, J M McKenzie.   

Abstract

Autoantibodies that occur in autoimmune thyroid disease and that interact with the TSH receptor are reviewed. Current limited understanding of the nature of the TSH receptor is detailed, and available assays for the different types of antibodies are described. The incidence, clinical significance, and interactions of the various antibodies are summarized.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3319587

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  9 in total

Review 1.  The measurement of antithyroid autoantibodies in the diagnosis and management of thyroid autoimmune disease.

Authors:  Z Kraiem
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.

Authors:  G Vannucchi; I Campi; M Bonomi; D Covelli; D Dazzi; N Currò; S Simonetta; P Bonara; L Persani; C Guastella; J Wall; P Beck-Peccoz; M Salvi
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

3.  Evidence supporting the identity in Graves' disease of thyroid-stimulating antibody and thyroid growth-promoting immunoglobulin G as assayed in FRTL5 cells.

Authors:  M Zakarija; S Jin; J M McKenzie
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

4.  Unlike thyrotropin, thyroid-stimulating antibodies do not activate phospholipase C in human thyroid slices.

Authors:  E Laurent; J Van Sande; M Ludgate; B Corvilain; P Rocmans; J E Dumont; J Mockel
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.

Authors:  P Bonara; G Vannucchi; I Campi; S Rossi; F Cantoni; C Frugoni; F Sbrozzi; C Guastella; S Avignone; P Beck-Peccoz; M Salvi
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

6.  Autoantibody stimulation of the human thyrotropin receptor: regulation of adenylate cyclase activity, thyroglobulin and thyroid peroxidase mRNA levels in primary cultures of Graves' thyroid tissue.

Authors:  K S Collison; J P Banga; P S Barnett; G C Huang; A M McGregor
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

7.  Value of the New Elastography Technique using Acoustic Radiation Force Impulse in Differentiation between Hashimoto's Thyroiditis and Graves' Disease.

Authors:  Mohamed Mohamed Hefeda
Journal:  J Clin Imaging Sci       Date:  2019-05-24

8.  Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions.

Authors:  Nupur Raychaudhuri; Roshini Fernando; Terry J Smith
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

9.  Growth hormone and insulin-like growth factor 1 affect the severity of Graves' disease.

Authors:  Alfredo Di Cerbo; Federica Pezzuto; Alessandro Di Cerbo
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.